| Not Yet Recruiting | Oncolytic Virus (H101) + SBRT + Chemotherapy + Targeted Therapy + Immunotherapy for Unresectable CRLM NCT07381309 | Jun Huang | Phase 2 |
| Recruiting | Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors NCT07397338 | Revolution Medicines, Inc. | Phase 1 / Phase 2 |
| Recruiting | A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of CBI-1214 T Cell NCT07321106 | Cartography Biosciences | Phase 1 |
| Recruiting | Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors NCT07349537 | Revolution Medicines, Inc. | Phase 1 |
| Not Yet Recruiting | A Phase Ib/II Trial of HS-20110 Combination Therapies in Advanced Colorectal Cancer Patients. NCT07283367 | Hansoh BioMedical R&D Company | Phase 1 / Phase 2 |
| Recruiting | A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With S NCT06682793 | A2 Biotherapeutics Inc. | Phase 1 / Phase 2 |
| Recruiting | The Phase 1b/IIa, Open-label, Dose Escalation and Dose Expansion to Evaluate Safety, Tolerability, and Prelimi NCT07204574 | Chang Gung Memorial Hospital | Phase 1 / Phase 2 |
| Recruiting | Addition of Antibiotics to Upfront Treatment Regimen for Colorectal Cancer NCT06728072 | Virginia Commonwealth University | Phase 2 |
| Recruiting | First in Human Study of TUB-030 in Patients With Advanced Solid Tumors NCT06657222 | Tubulis GmbH | Phase 1 / Phase 2 |
| Not Yet Recruiting | Lvosidenib (AK112) Combined With CapeOX and Radiotherapy in Patients With Unresectable Metastatic MSS-type Col NCT06593548 | Fudan University | Phase 2 |
| Recruiting | Cadonilimab Combined With Regorafenib as A Third-line Treatment in Patients With MSS CRLM NCT06455254 | Jin-hong Chen | Phase 2 |
| Recruiting | Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors NCT06445062 | Revolution Medicines, Inc. | Phase 1 / Phase 2 |
| Recruiting | A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With So NCT06051695 | A2 Biotherapeutics Inc. | Phase 1 / Phase 2 |
| Recruiting | A Study of SPX-303, a Bispecific Antibody Targeting LILRB2 and PD-L1 in Patients With Solid Tumors NCT06259552 | SparX Biotech(Jiangsu) Co., Ltd. | Phase 1 |
| Active Not Recruiting | Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and NCT06106308 | Cardiff Oncology | Phase 2 |
| Not Yet Recruiting | Clinical Study of Short-course Radiotherapy Followed by Fruquintinib Plus Sintilimab vs Bevacizumab Plus Capec NCT06195670 | Zhejiang Cancer Hospital | Phase 1 / Phase 2 |
| Withdrawn | Study of NGM707 in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies NCT07511972 | NGM Biopharmaceuticals, Inc | Phase 2 |
| Completed | Engaging Black Men in Colorectal Cancer Screening NCT05980182 | Virginia Commonwealth University | N/A |
| Active Not Recruiting | A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Participants With Solid Tumors NCT05736731 | A2 Biotherapeutics Inc. | Phase 1 / Phase 2 |
| Terminated | Study of Covalent Menin Inhibitor BMF-219 in Adult Patients With KRAS Driven Non-Small Cell Lung Cancer, Pancr NCT05631574 | Biomea Fusion Inc. | Phase 1 |
| Completed | A Study to Characterize the Safety, Tolerability, and Preliminary Efficacy of CFT1946 as Monotherapy and Combi NCT05668585 | C4 Therapeutics, Inc. | Phase 1 |
| Not Yet Recruiting | Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX07+HLX10 +mFOLFOX6 or HLX07 Monotherapy in P NCT05239650 | Shanghai Henlius Biotech | Phase 2 |
| Terminated | Microbiome in Colorectal Cancer Onset and Progression NCT05368688 | Viome | — |
| Recruiting | NKG2D CAR-T(KD-025) in the Treatment of Advanced NKG2DL+ Solid Tumors NCT05382377 | jianming xu | EARLY_Phase 1 |
| Unknown | Prospective Clinical Validation of a Novel Multitarget FIT in CRC Screening NCT05314309 | The Netherlands Cancer Institute | — |
| Unknown | Study of HL-085 and Vemurafinib in Metastatic Colorectal Cancer (mCRC) NCT05233332 | Shanghai Kechow Pharma, Inc. | Phase 2 |
| Completed | Glycan Mediated Immune Regulation With a Bi-Sialidase Fusion Protein (GLIMMER-01) NCT05259696 | Palleon Pharmaceuticals, Inc. | Phase 1 / Phase 2 |
| Active Not Recruiting | HBM4003 Combine With Toripalimab in Patients With Advanced NEN and Other Solid Tumors Study NCT05167071 | Harbour BioMed (Guangzhou) Co. Ltd. | Phase 1 |
| Recruiting | Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing NCT04981119 | A2 Biotherapeutics Inc. | — |
| Completed | JAB-21822 Activity in Adult Patients With Advanced Solid Tumors Harboring KRAS G12C Mutation NCT05002270 | Jacobio Pharmaceuticals Co., Ltd. | Phase 1 / Phase 2 |
| Unknown | The Efficacy of HLX208 (BRAF V600E Inhibitor) With Cetuximab for Metastatic Colorectal Cancer (mCRC) With BRAF NCT04984369 | Shanghai Henlius Biotech | Phase 2 |
| Active Not Recruiting | Study of Cabozantinib Plus TAS102 in mCRC as Salvage Therapy NCT04868773 | University of California, Irvine | Phase 1 |
| Terminated | Phase 1/2 Study to Evaluate Safety, PK and Efficacy of the MYC-Inhibitor OMO-103 in Solid Tumours NCT04808362 | Peptomyc S.L. | Phase 1 / Phase 2 |
| Active Not Recruiting | Study to Evaluate D-1553 in Subjects With Solid Tumors NCT04585035 | InventisBio Co., Ltd | Phase 1 / Phase 2 |
| Terminated | Evaluation of Bowel Cleansing Using the Pure-Vu System in Patients With History of Inadequate Bowel Preparatio NCT03922906 | Motus GI Medical Technologies Ltd | N/A |
| Completed | A Study of Telaglenastat (CB-839) in Combination With Palbociclib in Patients With Solid Tumors NCT03965845 | Calithera Biosciences, Inc | Phase 1 / Phase 2 |
| Terminated | Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors NCT03875313 | Calithera Biosciences, Inc | Phase 1 / Phase 2 |
| Withdrawn | Effect of WhatsApp Messenger on Uptake of CRC Screening Study NCT03337776 | Chinese University of Hong Kong | N/A |
| Completed | A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors NCT03665285 | NextCure, Inc. | Phase 1 / Phase 2 |
| Unknown | A Trial of SHR-1210 in Combination With SHR6390 in Patients With Advanced CRC, NSCLC and HCC NCT03601598 | Harbin Medical University | Phase 1 / Phase 2 |
| Completed | A Study of RGX-202-01 (Ompenaclid) as Combination Therapy in RAS Mutant Advanced Colorectal Cancer NCT03597581 | Inspirna, Inc. | Phase 1 |
| Completed | Evaluation of the Performance of the Motus Cleansing System (MCS) NCT03026075 | Motus GI Medical Technologies Ltd | N/A |
| Completed | Addressing Colorectal Cancer in South Florida Firefighters NCT05976282 | University of Miami | N/A |
| Completed | Donation of Post Mortem Tumor Tissues NCT03385980 | Niguarda Hospital | — |
| Completed | Clinical Investigational Plan: Evaluation of the Performance of the Motus Cleansing System NCT02572076 | Motus GI Medical Technologies Ltd | N/A |
| Active Not Recruiting | Intratumoral Budding (ITB) in Preoperative Biopsies of Colon and Rectal Cancer NCT03336658 | Insel Gruppe AG, University Hospital Bern | — |
| Completed | Evaluation of the Motus GI CleanUp System During Screening Colonoscopy NCT01838980 | Motus GI Medical Technologies Ltd | N/A |
| Completed | Evaluation of the Motus Gl CleanUp System During Screening Colonoscopy NCT02161549 | Motus GI Medical Technologies Ltd | — |
| Completed | Recombinant Vaccinia Virus Administered Intravenously in Patients With Metastatic, Refractory Colorectal Carci NCT01394939 | Jennerex Biotherapeutics | Phase 1 / Phase 2 |
| Unknown | Adjuvant Therapy(3 vs. 6 Months) With the FOLFOX 4 or XELOX for Stage II or Stage III Colon Cancer NCT01308086 | Hellenic Oncology Research Group | Phase 3 |
| Unknown | A Prospective Study Into the Risk of Colorectal Neoplasms in Individuals With a Family History of Advanced Ade NCT01593098 | Chinese University of Hong Kong | — |